Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroaki Echigo

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Biological & Pharmaceutical Bulletin|August 31, 2025
Probes with Tailored Pharmacokinetics for RadiotheranosticsMasayuki Munekane, Hiroaki Echigo, Takeshi Fuchigami, et al.
Molecules (Basel, Switzerland)|October 23, 2021
Synthesis and Evaluation of a Dimeric RGD Peptide as a Preliminary Study for Radiotheranostics with RadiohalogensHiroaki Echigo, Kenji Mishiro, Takeshi Fuchigami, et al.
Bioorganic & Medicinal Chemistry|July 11, 2022
Development and evaluation of a theranostic probe with RGD peptide introduced platinum complex to enable tumor-specific accumulationHiroaki Echigo, Kenji Mishiro, Masayuki Munekane, et al.
Molecules (Basel, Switzerland)|September 14, 2024
Differences in the Renal Accumulation of Radiogallium-Labeled (Glu)<sub>14</sub> Peptides Containing Different Optical Isomers of Glutamic AcidKazuma Ogawa, Kota Nishizawa, Kenji Mishiro, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 3, 2024
Optimizing the pharmacokinetics of an <sup>211</sup>At-labeled RGD peptide with an albumin-binding moiety via the administration of an albumin-binding inhibitorHiroaki Echigo, Masayuki Munekane, Takeshi Fuchigami, et al.
Molecular Pharmaceutics|August 17, 2021
<sup>68</sup>Ga- and <sup>211</sup>At-Labeled RGD Peptides for Radiotheranostics with MultiradionuclidesKazuma Ogawa, Hiroaki Echigo, Kenji Mishiro, et al.
Molecules (Basel, Switzerland)|July 12, 2025
Engineering a Radiohybrid PSMA Ligand with an Albumin-Binding Moiety and Pharmacokinetic Modulation via an Albumin-Binding Competitor for RadiotheranosticsSaki Hirata, Hiroaki Echigo, Masayuki Munekane, et al.
Nuclear Medicine and Biology|October 15, 2025
Evaluation of an <sup>211</sup>At-labeled RGD peptide in an orthotopic glioblastoma model by targeted alpha therapyHiroaki Echigo, Masayuki Munekane, Takeshi Fuchigami, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 11, 2023
Development of probes for radiotheranostics with albumin binding moiety to increase the therapeutic effects of astatine-211 (<sup>211</sup>At)Hiroaki Echigo, Kenji Mishiro, Masayuki Munekane, et al.
Nuclear Medicine and Biology|July 29, 2023
Astatine-211-labeled aza-vesamicol derivatives as sigma receptor ligands for targeted alpha therapyKazuma Ogawa, Kota Nishizawa, Kohshin Washiyama, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Biological & Pharmaceutical Bulletin|August 31, 2025
Probes with Tailored Pharmacokinetics for RadiotheranosticsMasayuki Munekane, Hiroaki Echigo, Takeshi Fuchigami, et al.
Molecules (Basel, Switzerland)|October 23, 2021
Synthesis and Evaluation of a Dimeric RGD Peptide as a Preliminary Study for Radiotheranostics with RadiohalogensHiroaki Echigo, Kenji Mishiro, Takeshi Fuchigami, et al.
Bioorganic & Medicinal Chemistry|July 11, 2022
Development and evaluation of a theranostic probe with RGD peptide introduced platinum complex to enable tumor-specific accumulationHiroaki Echigo, Kenji Mishiro, Masayuki Munekane, et al.
Molecules (Basel, Switzerland)|September 14, 2024
Differences in the Renal Accumulation of Radiogallium-Labeled (Glu)<sub>14</sub> Peptides Containing Different Optical Isomers of Glutamic AcidKazuma Ogawa, Kota Nishizawa, Kenji Mishiro, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 3, 2024
Optimizing the pharmacokinetics of an <sup>211</sup>At-labeled RGD peptide with an albumin-binding moiety via the administration of an albumin-binding inhibitorHiroaki Echigo, Masayuki Munekane, Takeshi Fuchigami, et al.
Molecular Pharmaceutics|August 17, 2021
<sup>68</sup>Ga- and <sup>211</sup>At-Labeled RGD Peptides for Radiotheranostics with MultiradionuclidesKazuma Ogawa, Hiroaki Echigo, Kenji Mishiro, et al.
Molecules (Basel, Switzerland)|July 12, 2025
Engineering a Radiohybrid PSMA Ligand with an Albumin-Binding Moiety and Pharmacokinetic Modulation via an Albumin-Binding Competitor for RadiotheranosticsSaki Hirata, Hiroaki Echigo, Masayuki Munekane, et al.
Nuclear Medicine and Biology|October 15, 2025
Evaluation of an <sup>211</sup>At-labeled RGD peptide in an orthotopic glioblastoma model by targeted alpha therapyHiroaki Echigo, Masayuki Munekane, Takeshi Fuchigami, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 11, 2023
Development of probes for radiotheranostics with albumin binding moiety to increase the therapeutic effects of astatine-211 (<sup>211</sup>At)Hiroaki Echigo, Kenji Mishiro, Masayuki Munekane, et al.
Nuclear Medicine and Biology|July 29, 2023
Astatine-211-labeled aza-vesamicol derivatives as sigma receptor ligands for targeted alpha therapyKazuma Ogawa, Kota Nishizawa, Kohshin Washiyama, et al.
Pageof 2